Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alutard Avanz
- Development stage
- Unknown
- Lead developer
- ALK Abelló
- Modality
- Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Alutard Avanz is a subcutaneous allergen immunotherapy (SCIT) product developed by ALK-Abelló for the treatment of allergic rhinitis and allergic asthma. It consists of standardized allergen extracts (such as grass pollen, tree pollen, or house dust mite) adsorbed onto aluminium hydroxide (alum) as an adjuvant. The alum adsorption provides a depot effect, allowing for a slow release of allergens and reducing the risk of systemic reactions while enhancing the immune response. Alutard Avanz is part of the SQ-standardized product family and is specifically formulated for a short up-dosing schedule. Its mechanism of action involves the induction of immune tolerance by shifting the immune system's response from a Th2-mediated allergic profile to a Th1 and regulatory T-cell (Treg) profile, typically resulting in increased levels of allergen-specific IgG4 antibodies and decreased IgE-mediated sensitivity.
- Brand names
- Alutard AvanzAlutard SQAlutard Avanz SQ
- Other names
- standardized allergen extractPhleum pratense allergen extractsubcutaneous grass-pollen allergen immunotherapy
02
Targets
A. annua-specific IgE (Artemisia annua-specific immunoglobulin E)Neuraminidase
Beyond the preview
Go deeper on Alutard Avanz.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alutard Avanz.